Strategic investment · Biotech

Regene4T secures investment from Neurotech Medical

The equity partnership gives Neurotech Medical exclusive handling rights over specified jointly developed research and preparations.

Neurotech Medical subscribed to a third-party share allotment by Regene4T. The January announcement did not disclose the amount or a named financing stage.

The companies plan to combine Regene4T’s neural-precursor extraction and nerve-function technologies with Neurotech Medical’s targeted nerve regeneration programme. Their agreement links the investment to joint research and commercial rights over resulting work.

Use of funds

Develop next-generation targeted nerve regeneration technology with Neurotech Medical

Funding history

Strategic investment · This roundUndisclosed

Sources

  1. ニューロテックメディカル、再生医療ベンチャーのリジェネフォーティーへ出資。次世代『標的神経再生医療™』の共同開発を開始prtimes.jp · Jan 7, 2026